Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19
Details : Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike, Envelope, and Membrane (M) that they have selected for their vaccine candidate.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 04, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triple Antigen Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Premas Biotech to Develop Vaccine Against COVID-19 Based on Multi-Antigenic Approach
Details : Premas Biotech has adopted a three-pronged approach to develop multi subunit vaccine, using recombinantly expressed antigens Spike, Envelope, and Membrane proteins in multiple formats.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 30, 2020
Lead Product(s) : Triple Antigen Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coronavirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Akers Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech
Details : Akers will in-license a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform and partner with Premas to seek FDA approval.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 24, 2020
Lead Product(s) : Coronavirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Akers Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement